Researchers are investigating alternative strategies to life-long anti-retroviral treatment. An example of such a study is the antibody-mediated protection (AMP) proof-of-concept trials* that tested the capability of VRC01#, HIV-specific broadly neutralising antibody (bNAb) to prevent HIV-1 acquisition.
Participants in the AMP trials received 10 administrations of either high (30mg/kg) or low (10m/kg) lose dose of VRC01 at 8-week intervals for 20-months, and were routinely monitored (every 4 weeks) for the acquisition of HIV. Unfortunately, administration of VRC01 did not significantly lower incidence of HIV acquisition demonstrated by an efficacy of 26.6% in HVTN704/HPTN085 and 8.8% in HVTN 703/HPTN 081. Analysis of HIV viral isolates demonstrated some efficacy (75%) against VRC01-sensitive (80% inhibitory concentration of 1ug/mL) HIV strains which constituted minority of isolates (10% of infected individuals) and was associated with a much lower viral load at onset of infection than individuals infected with VRC01 resistant strains.
In summary, despite the disappointing efficacy of VRC01 against HIV acquisition. The AMP trial did demonstrate a proof of concept of the trial concept, highlighting the need for future studies to test the potential efficacy of a cocktail of HIV-specific bnAbs that bind to different HIV antigens.
- *HIV Vaccine Trials Network [HVTN] 704/HIV Prevention Trials Network [HPTN] 085 phase 2b conducted in North America, South America, and Europe and enrolled men.
- *HVTN 703/HPTN 081 phase 2b conducted in Sub-saharan Africa enrolled women.
- # VRC01 bnAb binds the HIV envelope protein CD4 binding site, and has been shown to have a wide coverage of HIV subtype B and C strains in vitro studies.
Summary by Cheleka AM Mpande